Screener
Exelixis EXEL Net product revenues — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Exelixis’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q3 2026
- Accession
- 0000939767-26-000098
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Net product revenues | $573,025 | $520,014 | $1,128,002 | $1,033,297 |
| Collaboration revenues | 55,665 | 48,247 | 111,500 | 90,411 |
| Total revenues | 628,690 | 568,261 | 1,239,502 | 1,123,708 |
| Operating expenses: | ||||
| Cost of goods sold | 20,657 | 19,470 | 40,610 | 38,642 |
| Research and development | 211,987 | 200,356 | 411,903 | 412,589 |
| Selling, general and administrative | 147,632 | 134,859 | 287,234 | 272,042 |
Item 1. Financial Statements.
FAQ
- What is Exelixis's net product revenues — total revenues?
- Exelixis (EXEL) reported net product revenues — total revenues of $573.03M in Q2 2026.
- How has Exelixis's net product revenues — total revenues changed year-over-year?
- Exelixis's net product revenues — total revenues increased by 10.2% year-over-year, from $520.01M to $573.03M.
- What is the long-term trend for Exelixis's net product revenues — total revenues?
- Over 4 years (2021 to 2025), Exelixis's net product revenues — total revenues has grown at a 18.5% compound annual growth rate (CAGR), from $1.08B to $2.12B.
- What does net product revenues — total revenues mean?
- This metric represents the total gross revenue generated from the sale of pharmaceutical products, net of variable considerations such as rebates, chargebacks, discounts, and returns. It serves as the primary indicator of the commercial success and market adoption of the company's therapeutic portfolio. By focusing on product-specific sales, this metric isolates the core operational performance of the commercial business from licensing, royalty, or collaboration-based revenue streams.
Ask your AI about Exelixis's net product revenues — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude